期刊
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY
卷 314, 期 4, 页码 1529-1543出版社
AMER PHYSIOLOGICAL SOC
DOI: 10.1152/ajplung.00465.2017
关键词
cystic fibrosis; cystic fibrosis transmembrane conductance regulator; ivacaftor; lumacaftor; N-of-1 study; personalized medicine
资金
- National Institute of Diabetes and Digestive and Kidney Diseases [DK080834, DK093045]
- Cystic Foundation [HUANG17F0, ARORA16F0, NAREN14XX0, NAREN1610, CLANCY15R0]
Cystic fibrosis (CF) is the most common life-shortening genetic disease affecting similar to 1 in 3,500 of the Caucasian population. CF is caused by mutations in the CF transmembrane conductance regulator (CFTR) gene. To date, more than 2,000 CFTR mutations have been identified, which produce a wide range of phenotypes. The CFTR protein, a chloride channel, is normally expressed on epithelial cells lining the lung, gut, and exocrine glands. Mutations in CFTR have led to pleiotropic effects in CF patients and have resulted in early morbidity and mortality. Research has focused on identifying small molecules, or modulators, that can restore CFTR function. In recent years, two modulators, ivacaftor (Kalydeco) and lumacaftor/ivacaftor (Orkambi), have been approved by the U.S. Food and Drug Administration to treat CF patients with certain CFTR mutations. The development of these modulators has served as proof-of-concept that targeting CFTR by modulators is a viable therapeutic option. Efforts to discover new modulators that could deliver a wider and greater clinical benefit are still ongoing. However, traditional randomized controlled trials (RCTs) require large numbers of patients and become impracticable to test the modulators' efficacy in CF patients with CFTR mutations at frequencies much lower than 1%, suggesting the need for personalized medicine in these CF patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据